Reversing Time: The First Human Clinical Trial for Cellular Rejuvenation Therapy

Explore the frontier of longevity science as we examine Life Biosciences' groundbreaking human clinical trial for ER-100. This therapy, rooted in epigenetic reprogramming, aims to reverse cellular aging to treat vision loss. We analyze the scientific promise of restoring retinal ganglion cells, the strategic choice of targeting eye conditions, and the cautious perspectives from experts regarding safety and the hype surrounding anti-aging technology. Join us as we discuss whether this trial marks the beginning of a new era in medicine or if the risks of cellular manipulation remain too high for human application.

📥 Connect with The Well-Built Life